200,000+ products from a single source!
sales@angenechem.com
130656-51-8 | 2,4(1H,3H)-Pyrimidinedione, 6-[[2-[(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-, hydrochloride (1:1)
CAS No: 130656-51-8 Catalog No: AG000URC MDL No:MFCD00892243
Product Description
Catalog Number:
AG000URC
Chemical Name:
2,4(1H,3H)-Pyrimidinedione, 6-[[2-[(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-, hydrochloride (1:1)
CAS Number:
130656-51-8
Molecular Formula:
C19H28ClN5O5
Molecular Weight:
441.9091
MDL Number:
MFCD00892243
IUPAC Name:
6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione;hydrochloride
InChI:
InChI=1S/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H
InChI Key:
YPVGGQKNWAKOPX-UHFFFAOYSA-N
SMILES:
OCCN(CCNc1cc(=O)n(c(=O)n1C)C)CCCc1ccc(cc1)[N+](=O)[O-].Cl
UNII:
TPP5R0MDQS
Properties
Complexity:
613
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
441.178g/mol
Formal Charge:
0
Heavy Atom Count:
30
Hydrogen Bond Acceptor Count:
7
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
441.913g/mol
Monoisotopic Mass:
441.178g/mol
Rotatable Bond Count:
10
Topological Polar Surface Area:
122A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Why are most phospholipidosis inducers also hERG blockers? | Archives of toxicology 20171201 |
| Nifekalant enlarged the transmural activation-recovery interval difference as well as the peak-to-end interval on surface ECG in a patient with short-QT syndrome. | Journal of cardiovascular electrophysiology 20120801 |
| Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates. | Journal of biomolecular screening 20120701 |
| Pharmacologic atrial defibrillation by drug delivery into the temporarily occluded coronary sinus. A canine study. | International heart journal 20120101 |
| Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome. | Circulation journal : official journal of the Japanese Circulation Society 20120101 |
| A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents. | Biochemical and biophysical research communications 20111111 |
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | Journal of medicinal chemistry 20110714 |
| Deep anesthesia suppresses ventricular tachyarrhythmias in rabbit model of the acquired long QT syndrome. | Circulation journal : official journal of the Japanese Circulation Society 20110101 |
| Effect of the ATP-sensitive K⁺ channel opener nicorandil in a canine model of proarrhythmia. | International heart journal 20110101 |
| Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride. | Circulation journal : official journal of the Japanese Circulation Society 20101101 |
| Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. | Resuscitation 20100801 |
| Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. | Stem cell research 20100501 |
| Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. | Journal of cardiovascular pharmacology 20100401 |
| Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. | Resuscitation 20100101 |
| Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. | Circulation journal : official journal of the Japanese Circulation Society 20091101 |
| Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties. | Pacing and clinical electrophysiology : PACE 20080901 |
| The effects of nifekalant hydrochloride on the QT dispersion after direct-current defibrillation. | Osaka city medical journal 20080601 |
| Human atrial natriuretic peptide suppresses torsades de pointes in rabbits. | Circulation journal : official journal of the Japanese Circulation Society 20080501 |
| Clinical study of the acute effects of intravenous nifekalant on the defibrillation threshold in patients with persistent and paroxysmal atrial fibrillation. | Circulation journal : official journal of the Japanese Circulation Society 20080101 |
| Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter. | Pacing and clinical electrophysiology : PACE 20071001 |
| [Despite medication, overdrive pacing is required to stabilize the electrical storm associated with acute coronary syndrome: a case report]. | Journal of cardiology 20071001 |
| [Case of intractable ventricula fibrillation by a multicomponent dietary supplement containing ephedra and caffeine overdose]. | Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology 20070701 |
| Analysis of arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventricular block heart. | Journal of pharmacological sciences 20070201 |
| Mechanisms of destabilization and early termination of spiral wave reentry in the ventricle by a class III antiarrhythmic agent, nifekalant. | American journal of physiology. Heart and circulatory physiology 20070101 |
| Is the combination therapy of IKr-channel blocker and left stellate ganglion block effective for intractable ventricular arrhythmia in a cardiopulmonary arrest patient? | Cardiology journal 20070101 |
| Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant. | Channels (Austin, Tex.) 20070101 |
| Effect of nifekalant on acute electrical remodelling in rapid atrial pacing canine model. | Chinese medical journal 20061220 |
| Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride. | Journal of cardiovascular pharmacology 20061201 |
| Reduced inotropic effect of nifekalant in failing hearts in rats. | The Journal of pharmacology and experimental therapeutics 20060901 |
| Effects of antiarrhythmic drugs on apoptotic pathways in H9c2 cardiac cells. | Journal of pharmacological sciences 20060801 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias. | Circulation journal : official journal of the Japanese Circulation Society 20060501 |
| Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. | Circulation journal : official journal of the Japanese Circulation Society 20060401 |
| [Strategy for cardiac arrhythmias in acute coronary syndrome]. | Nihon rinsho. Japanese journal of clinical medicine 20060401 |
| [Present status in and prospects for anti-arrhythmic drug therapy: How to use type III anti-arrhythmic agents]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060210 |
| Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)? : comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis. | Circulation journal : official journal of the Japanese Circulation Society 20060101 |
| Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation. | Circulation journal : official journal of the Japanese Circulation Society 20051001 |
| Optical imaging of spiral waves: pharmacological modification of spiral-type excitations in a 2-dimensional layer of ventricular myocardium. | Journal of electrocardiology 20051001 |
| Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment. | Journal of cardiovascular electrophysiology 20050701 |
| Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease. | International heart journal 20050701 |
| Effect of nifekalant, a class III anti-arrhythmic agent, on Ca2+ waves in rat intact trabeculae. | Circulation journal : official journal of the Japanese Circulation Society 20050601 |
| Combined effects of nifekalant and lidocaine on the spiral-type re-entry in a perfused 2-dimensional layer of rabbit ventricular myocardium. | Circulation journal : official journal of the Japanese Circulation Society 20050501 |
| Effect of IKr blocker nifekalant on atrial action potential duration after successful internal cardioversion of chronic atrial fibrillation. | Pacing and clinical electrophysiology : PACE 20050501 |
| Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation. | Pacing and clinical electrophysiology : PACE 20050101 |
| Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation. | Japanese heart journal 20040701 |
| Development of a halothane-adrenaline arrhythmia model using in vivo Guinea pigs. | Journal of pharmacological sciences 20040601 |
| Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. | Journal of cardiovascular pharmacology 20040501 |
| Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation. | Pacing and clinical electrophysiology : PACE 20040201 |
| Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach. | Circulation journal : official journal of the Japanese Circulation Society 20030801 |
| [Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest]. | Journal of cardiology 20030301 |
| Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action. | European journal of pharmacology 20021213 |
| Pretreatments with a novel pure potassium channel blocker, Nifekalant, were effective in the electrical atrial defibrillation: a report of two cases. | Cardiovascular drugs and therapy 20021201 |
| Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia. | Journal of cardiovascular pharmacology 20021101 |
| [Recent findings on the dromotropic actions of the class III antiarrhythmic agents]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20021101 |
| [Successful hybrid therapy combined with oral bepridil and ICD in a patient with amiodarone refractory life-threatening ventricular tachyarrhythmia associated with ischemic cardiomyopathy]. | Journal of UOEH 20020901 |
| [Management of lethal ventricular arrhythmias after cardiac surgery]. | Nihon rinsho. Japanese journal of clinical medicine 20020701 |
| Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure. | Journal of cardiology 20020301 |
| [Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20020201 |
| Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium. | Japanese circulation journal 20010101 |
| Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction. | Journal of electrocardiology 20010101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.